GDH1 Antibody

What is GDH1 and what are its key structural characteristics?

GDH1 (glutamate dehydrogenase 1) is a 558 amino acid protein encoded by the human GLUD1 gene. It belongs to the Glu/Leu/Phe/Val dehydrogenases family and functions as a key metabolic enzyme. The protein's substantial length provides multiple epitopes for antibody development, allowing researchers to target specific domains depending on experimental needs. Understanding the full protein structure is essential when selecting antibodies for specific applications, as certain domains may be more accessible than others depending on experimental conditions .

What types of GDH1 antibodies are currently available for research?

Researchers have access to a diverse range of GDH1 antibodies, including:

• Host origin: Primarily rabbit-derived polyclonal antibodies

• Format variations: Unconjugated, biotin-conjugated, and fluorophore-conjugated (e.g., APC)

• Application-specific antibodies: Those optimized for Western blotting, ELISA, immunohistochemistry, immunocytochemistry, and flow cytometry

• Target specificity: Antibodies recognizing specific post-translational modifications (e.g., acetylated GDH1 at K503 or K527)

The selection depends on experimental requirements, with over 100 commercial antibody products currently available across multiple suppliers .

How should researchers validate GDH1 antibody specificity?

Proper validation is critical for ensuring experimental reliability. A comprehensive validation approach should include:

• Positive and negative controls: Using tissues/cells with known GDH1 expression profiles

• Knockdown/knockout verification: Testing antibody reactivity in GDH1-depleted systems

• Western blot analysis: Confirming single band detection at the expected molecular weight (~61 kDa for human GDH1)

• Cross-reactivity assessment: Testing against related family members, particularly in multi-species studies

• Peptide competition assays: Pre-incubating antibody with immunizing peptide to confirm specific binding

For specialized applications like post-translational modification studies, researchers should validate antibodies against purified GDH1 proteins expressed in E. coli or mammalian cells with or without the specific modification .

What are the optimal protocols for GDH1 detection by immunohistochemistry?

For effective IHC detection of GDH1 in tissue samples:

• Fixation: 10% neutral-buffered formalin for 24-48 hours

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) for 20 minutes

• Blocking: 5% normal serum corresponding to secondary antibody host for 1 hour

• Primary antibody: Dilute GDH1 antibody 1:100-1:500 (optimize for each antibody) and incubate overnight at 4°C

• Detection system: HRP-conjugated secondary antibody with DAB visualization

• Counterstaining: Hematoxylin for nuclear visualization

This protocol has been effectively used to assess GDH1 expression in colorectal cancer tissues, allowing correlation with HIF1α levels and cancer progression .

How can researchers effectively use GDH1 antibodies for studying protein-protein interactions?

To investigate GDH1 interactions with partners like the EGLN1/HIF1α complex:

• Co-immunoprecipitation:

  • Lyse cells in non-denaturing buffer containing protease inhibitors and deacetylase inhibitors (10 mM NAM)

  • Pre-clear lysate with protein A/G beads

  • Incubate with GDH1 antibody overnight (4°C)

  • Capture complexes with protein A/G beads

  • Wash stringently and elute for Western blot analysis of interaction partners

• Proximity Ligation Assay (PLA):

  • Fix cells on coverslips with 4% paraformaldehyde

  • Permeabilize with 0.2% Triton X-100

  • Block with 5% BSA

  • Incubate with primary antibodies against GDH1 and potential interaction partner

  • Proceed with PLA protocol using species-specific PLA probes

  • Analyze fluorescent signals indicating proteins in close proximity (<40 nm)

These approaches have successfully demonstrated GDH1 interaction with the EGLN1/HIF1α complex, particularly after GDH1 acetylation at K527 under hypoxic conditions .

What considerations are important when using GDH1 antibodies for flow cytometry?

For optimal flow cytometry results:

• Cell preparation: Single-cell suspensions with viability >90%

• Fixation/permeabilization: Use commercial kits optimized for intracellular proteins

• Antibody selection: Use directly conjugated antibodies (e.g., APC-conjugated) when possible

• Titration: Determine optimal antibody concentration (typically 0.1-10 μg/ml)

• Controls:

  • Unstained cells

  • Isotype control

  • FMO (Fluorescence Minus One)

  • Positive control (cells with known GDH1 expression)

  • Negative control (GDH1-knockout cells if available)

• Analysis parameters:

  • Exclude doublets and dead cells

  • Use appropriate compensation for multi-color panels

  • Analyze shift in fluorescence intensity compared to controls

APC-conjugated GDH1 antibodies are particularly effective for flow cytometry applications due to their bright fluorescence and minimal spectral overlap with common fluorophores .

How can researchers study GDH1 post-translational modifications using specific antibodies?

For investigating GDH1 acetylation and other modifications:

• Generation of modification-specific antibodies:

  • Design peptides containing the modified residue (e.g., acetylated K503 or K527)

  • Immunize rabbits with synthetic peptides

  • Purify antibodies using affinity chromatography

  • Validate with acetylated and non-acetylated GDH1 proteins

• Experimental application:

  • Treat cells with deacetylase inhibitors (e.g., NAM) to preserve acetylation

  • Immunoprecipitate with pan-GDH1 antibody, then detect acetylation with site-specific antibody

  • Alternatively, immunoprecipitate with acetylation-specific antibody to enrich modified GDH1

• Control experiments:

  • Use GDH1 mutants (K503R, K527R) to confirm specificity

  • Include competing peptides to verify epitope specificity

This approach has successfully identified hypoxia-induced acetylation of GDH1 at K527, which anchors GDH1 to the EGLN1/HIF1α complex and affects HIF1α stability .

What are common troubleshooting strategies for GDH1 antibody experiments?

When encountering issues with GDH1 antibody applications:

For acetylation-specific antibodies, maintaining deacetylase inhibition throughout sample preparation is crucial to prevent loss of the modification .

How can GDH1 enzymatic activity be correlated with antibody-based detection?

To connect GDH1 protein levels with enzymatic activity:

• Parallel sample processing:

  • Divide cell/tissue lysate for both Western blot and activity assay

  • Ensure identical sample handling to maintain protein integrity

• GDH1 activity measurement:

  • Forward reaction: 100 mM Tris (pH 8.0), 50 mM L-Glutamate, 1 mM NAD+, monitor NADH production at 340 nm

  • Reverse reaction: 100 mM Tris (pH 7.5), 100 mM NH4Cl, 0.1 mM NADH, monitor NADH consumption at 340 nm

• Data correlation:

  • Normalize activity to GDH1 protein levels determined by Western blot

  • Calculate specific activity (activity units per μg GDH1 protein)

  • Compare across experimental conditions or between wild-type and mutant GDH1

This approach can reveal functional consequences of modifications like K503 acetylation, which has been shown to affect GDH1 enzymatic activity .

How does GDH1 contribute to cancer progression and what methods can assess this function?

GDH1 plays significant roles in cancer development through multiple mechanisms:

• HIF1α stability regulation:

  • Under hypoxic conditions, GDH1 undergoes acetylation at K527

  • Acetylated GDH1 targets the EGLN1/HIF1α complex

  • This interaction inhibits HIF1α hydroxylation and subsequent degradation

  • Result: Stabilized HIF1α promotes cancer progression

• Experimental approaches to study this mechanism:

  • In vivo models: Tissue-specific GDH1 knockout mice (e.g., intestine-specific GDH1 knockout) show reduced colorectal cancer progression after AOM/DSS treatment

  • Histological analysis: IHC staining of GDH1 and HIF1α in cancer tissues reveals correlation between GDH1 expression and HIF1α levels

  • Molecular analysis: Western blotting for HIF1α protein levels in GDH1-depleted versus control tissues

  • Functional readouts: Analysis of HIF1α target genes (GLUT1, HK1, PGK1, CCND1) to assess downstream effects

These approaches have demonstrated that intestine-specific GDH1 depletion significantly reduces colorectal cancer occurrence, delays tumor appearance, and prolongs survival in mouse models .

What is the current understanding of GDH1 acetylation in hypoxia response?

GDH1 acetylation represents a critical regulatory mechanism in hypoxia response:

• Acetylation sites and regulation:

  • K503 and K527 are key acetylation sites on GDH1

  • Hypoxia induces GDH1 acetylation via p300 acetyltransferase

  • Acetylation is reversible, suggesting dynamic regulation

• Functional consequences:

  • K527 acetylation: Anchors GDH1 to the EGLN1/HIF1α complex

  • K503 acetylation: Constrains EGLN1 hydroxylase activity

  • Both modifications reduce αKG binding to EGLN1

  • Net effect: Prevention of HIF1α hydroxylation and subsequent degradation

• Analytical methods:

  • Site-specific acetylation antibodies for direct detection

  • Mass spectrometry analysis for comprehensive acetylation profiling

  • Functional assays measuring EGLN1 activity with acetylated versus non-acetylated GDH1

  • Mutation studies (K503R/Q, K527R/Q) to mimic or prevent acetylation

This detailed understanding of GDH1 acetylation provides potential targets for therapeutic intervention in hypoxia-dependent pathologies .

How can researchers accurately measure the interaction between GDH1 and EGLN1/HIF1α complex?

To quantitatively assess this critical interaction:

• Binding assays:

  • Co-immunoprecipitation with quantitative Western blotting

  • ELISA-based protein-protein interaction assays

  • Surface plasmon resonance for real-time binding kinetics

  • Microscale thermophoresis for binding affinity determination

• Functional interaction assays:

  • EGLN1 hydroxylase activity assay using synthetic HIF peptides

  • αKG binding studies:

    • 14C-αKG-EGLN1 binding assay: Incubate purified EGLN1 with 14C-labeled αKG, measure radioactivity

    • LC-MS-based protein-bound metabolite assay: Measure αKG release after protein digestion

• Mutation-based approaches:

  • Compare wild-type GDH1 versus K503R/Q and K527R/Q mutants

  • Use EGLN1 R383/398A mutant (which cannot bind αKG) as a negative control

These methods have revealed that GDH1 acetylation at both K503 and K527 is essential for reducing αKG binding to EGLN1, thereby preventing HIF1α hydroxylation under hypoxic conditions .

What emerging techniques are advancing GDH1 antibody applications in precision medicine?

Novel approaches expanding GDH1 research into clinical applications include:

• Single-cell protein analysis:

  • Mass cytometry (CyTOF) with metal-conjugated GDH1 antibodies

  • Single-cell Western blotting for heterogeneity assessment

  • Imaging mass cytometry for spatial protein analysis in tissues

• Antibody-based therapeutics:

  • Antibody-drug conjugates targeting GDH1-overexpressing cells

  • Intrabodies for manipulating GDH1 function in living cells

  • Bispecific antibodies targeting GDH1 and effector proteins

• Diagnostic applications:

  • Multiplex immunoassays with GDH1 and related biomarkers

  • Circulating tumor cell detection using GDH1 antibodies

  • Tissue microarray analysis correlating GDH1 with patient outcomes

• Advanced imaging:

  • Super-resolution microscopy with GDH1 antibodies

  • Intravital imaging of GDH1-antibody conjugates in animal models

  • FRET-based assays for monitoring GDH1 interactions in living cells

These emerging technologies are particularly relevant for studying GDH1's role in cancer progression and may lead to novel diagnostic and therapeutic strategies .